BENZOCAINE; DEXTROMETHORPHAN HYDROBROMIDE; MENTHOL

AU:B3 G04BD10(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only (S)-2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl] pyrrolidin-3-yl] -2,2-diphenyl-acetamide 133099-04-4Y 444031 321 DB00496Y 392054Y APG9819VLM D03654Nas salt:D01699N CHEBI:391960Y ChEMBL1346Y DTXSID2048290 Interactive image O=C(N)C(c1ccccc1)(c2ccccc2)[C@H]3CN(CC3)CCc5cc4c(OCC4)cc5 InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1YKey:HXGBXQDTNZMWGS-RUZDIDTESA-NY Darifenacin(trade nameEnablexin United States and Canada,Emselexin the European Union) is amedicationused to treaturinary incontinencedue to anoveractive bladder.It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed byNovartis. In 2010, the US rights were sold toWarner ChilcottforUS$400 million.